Table 14 (abstract P211). Risk factors for infections in JIA patients by multivariate analysis. (REF: reference item)
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two
Patients with infections 689 | Multivariate analysis OR (95%CI) | |
|---|---|---|
Drug Therapy Only NSAIDs and Intraarticular Steroids (REF) | ||
-Rituximab ± Steroids ± DMARDS | 12/16 (75%) | 111.8 (10.7-999.9) |
-MTX + Biologics + Steroids | 95/422 (23%) | 10.5 (6.5-17.0) |
-MTX + Steroids | 47/207 (23%) | 11.9 (7.0-20.2) |
-Other combinations | 102/689 (15%) | 7.6 (4.8-12.0) |
-Only MTX | 157/1418 (11%) | 5.1 (3.3-7.9) |
-MTX + Biologics | 181/2055 (9%) | 3.7 (2.4-5.8) |
-Only Biologics | 71/1077 (7%) | 2.7 (1.7-4.3) |
Diagnosis (Oligo Persistent arthritis as REF) | ||
-Other JIA categories with polyarticular course | 1.3 (1.1-1.6) | |
-Systemic arthritis | 1.7 (1.3-2.3) | |
Age at JIA diagnosis (cut-off ≤7.7) | 2.3 (1.9-2.7) | |
ANA (2 positive >1:160) | 1.6 (1.3-1.9) | |